{
  "docId": "019de517-44b3-71b5-8a8d-243b41bb1797",
  "docSlug": "c77cf9536b998c2f906519be4212f807",
  "documentTitle": "GH Research | Investor Presentation Deck | 30 slides",
  "authorId": "gh-research",
  "authorName": "GH Research",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 30,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 20,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de517-44b3-71b5-8a8d-243b41bb1797/11",
  "deckHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797",
  "deckJsonHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797.json",
  "deckAnchorHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.479,
        "w": 0.389,
        "x": 0.069,
        "y": 0.179
      },
      "kind": "list",
      "text": "Study Safety Group review\nNo SAEs\nAll ADRs mild, except two moderate (*)\nAll ADRs resolved spontaneously\nInhalation well-tolerated\nNo noteworthy changes in vital parameters, except for temporary, non-clinically relevant increase in heart rate and blood pressure shortly after administration of GH001\nNo clinically significant changes in safety laboratory analyses, psychiatric safety assessments or measures of cognitive function",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e466480a-6819-447a-ba79-09e0c4e3660e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.602,
        "x": 0.069,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "SAE, Serious Adverse Event; ADR, Adverse Drug Reaction, an adverse event with a relationship code to the investigational product of definite, probable, or possible, or where code is missing; IDR, Individualized Dosing Regimen",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5aa064d0-8e18-456f-ad60-7e4ba7038a23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.019,
        "w": 0.147,
        "x": 0.78,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "16 mg (n=1); 6-12 mg (n=2); 6-12-18 mg (n=1)",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d2809c2d-4c9b-4b5e-9736-7bbc75348b6a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.688,
        "w": 0.52,
        "x": 0.416,
        "y": 0.166
      },
      "kind": "table",
      "text": "ADRs, MedDRA Preferred Term, Part A (Single Dose), 2 mg (n=4), 6 mg (n=6), 12 mg (n=4), 18 mg (n=4), Part B (IDR), IDR1 (n=4), Number of Events, Abnormal dreams, 1, Anxiety, 1, 1, Clumsiness, 1, Confusional state, 1, Euphoric mood, 1, Fatigue, 1, 1*, Feeling hot, 1, Flashback, 1, Hallucination, 1, Head discomfort, 1, Headache, 2, 1, 1, Heart rate increased, 1*, Hyperacusis, 1, Insomnia, 1, Mental fatigue, 1, Nausea, 2, 1, 1, 2, Vision blurred, 1",
      "attrs": {
        "header_cols": 1,
        "header_rows": 3
      },
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e35de57-97cb-4e73-93d7-4f647bd04384",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.701,
        "x": 0.069,
        "y": 0.07
      },
      "kind": "title",
      "text": "Part A (Single Dose) and Part B (IDR) – Safety",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "532fd9ba-9850-474d-a47c-e383d702b75c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 30,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e59b812c-5781-40d1-880d-5eb666da502e",
      "evidence": "The document emphasizes the limitations of current treatments and the potential of GH001",
      "position": 0,
      "objective": "Highlight the need for more effective depression treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 30,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "a0a779b4-6b2d-4f03-ae8f-5683cc3e54fa",
      "evidence": "The document presents a clear 'why' for GH001, highlighting its potential to provide ultra-rapid, durable remissions",
      "position": 1,
      "objective": "Explain why GH001 is a necessary solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}